Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Gutman

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Transplantation|February 10, 2009
Prospective monitoring for alloimmunization in cord blood transplantation: "virtual crossmatch" can be used to demonstrate donor-directed antibodiesJonathan A Gutman, Susan K McKinney, Shalini Pereira, et al.
Bone Marrow Transplantation|October 14, 2021
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60Daniel A Pollyea, Amanda Winters, Christine McMahon, et al.
Blood|September 23, 2011
Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsFilippo Milano, Steven A Pergam, Hu Xie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2018
Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort ComparisonPrashant Sharma, Daniel A Pollyea, Clayton A Smith, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 16, 2014
Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalizationKatrina M Babilonia, Larry K Golightly, Jonathan A Gutman, et al.
Bone Marrow Transplantation|May 15, 2023
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapseAndrew Kent, Marc Schwartz, Christine McMahon, et al.
Leukemia & Lymphoma|December 30, 2020
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemiaDiana Abbott, Evan Cherry, Maria Amaya, et al.
Blood Advances|July 25, 2020
Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter studyFilippo Milano, Jonathan A Gutman, H Joachim Deeg, et al.
Leukemia & Lymphoma|May 30, 2024
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemiaJacob Fang, Grace Bosma, Dara Aisner, et al.
Blood Advances|May 23, 2020
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplantPrashant Sharma, Enkhtsetseg Purev, Bradley Haverkos, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Transplantation|February 10, 2009
Prospective monitoring for alloimmunization in cord blood transplantation: "virtual crossmatch" can be used to demonstrate donor-directed antibodiesJonathan A Gutman, Susan K McKinney, Shalini Pereira, et al.
Bone Marrow Transplantation|October 14, 2021
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60Daniel A Pollyea, Amanda Winters, Christine McMahon, et al.
Blood|September 23, 2011
Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsFilippo Milano, Steven A Pergam, Hu Xie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2018
Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort ComparisonPrashant Sharma, Daniel A Pollyea, Clayton A Smith, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 16, 2014
Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalizationKatrina M Babilonia, Larry K Golightly, Jonathan A Gutman, et al.
Bone Marrow Transplantation|May 15, 2023
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapseAndrew Kent, Marc Schwartz, Christine McMahon, et al.
Leukemia & Lymphoma|December 30, 2020
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemiaDiana Abbott, Evan Cherry, Maria Amaya, et al.
Blood Advances|July 25, 2020
Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter studyFilippo Milano, Jonathan A Gutman, H Joachim Deeg, et al.
Leukemia & Lymphoma|May 30, 2024
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemiaJacob Fang, Grace Bosma, Dara Aisner, et al.
Blood Advances|May 23, 2020
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplantPrashant Sharma, Enkhtsetseg Purev, Bradley Haverkos, et al.
Pageof 6